GlaxoSmithKline Seeks to Sell Flu Vaccine in U.S.
From Associated Press
GlaxoSmithKline is hoping to enter the U.S. flu-vaccine market, citing the nationwide shortage last year that led to lines for the vaccines.
The company applied to the Food and Drug Administration for permission to sell Fluarix, which is sold in more than 75 countries.
Start your day right
Sign up for Essential California for news, features and recommendations from the L.A. Times and beyond in your inbox six days a week.
You may occasionally receive promotional content from the Los Angeles Times.
